Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Upstart Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Upstart Holdings Inc trades at $32.63 (market cap $3.13B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.7× Upstart Holdings Inc's market cap. Which is the better fit depends on your goals.
| ALNY | UPST | |
|---|---|---|
Market Cap | $39.89B | $3.13B |
Sector | Health | Financials |
52-Week High | $491.22 | $84.13 |
52-Week Low | $278.09 | $24.22 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Upstart Holdings (UPST) trades at $32.74, down 1.47% on the day, with a bullish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with $53.60M net income on $1.02B revenue, though recent quarterly earnings missed expectations. Analyst consensus is mixed with a $42.00 price target, and the stock is positioned between key support at $32 and resistance at $34.
The outlook hinges on execution of AI lending growth and funding stability, with upside potential from product expansion, but risks include margin pressure, debt levels, and macroeconomic sensitivity. The stock offers a speculative growth opportunity amid improving fundamentals but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
